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Bad bedfellows – autonomic dysfunction, inﬂammation, and diabetes! Are they related?
How? Evidence suggests the activation of inﬂammatory cytokines like IL-6 and TNFa
in newly diagnosed type 2 diabetes and that the inﬂammatory change correlates with
abnormalities in sympathovagal balance. Dysfunction of the autonomic system predicts
cardiovascular risk and sudden death in patients with type 2 diabetes. It occurs in pre-
diabetes, providing opportunities for early intervention. The importance of recognizing
autonomic dysfunction as a predictor of morbidity and mortality with intensiﬁcation of
treatment suggests that all patients with type 2 diabetes at onset, and those with type
1 diabetes after 5years should be screened for autonomic imbalance.These tests can be
performed at the bedside with real time output of information – within the scope of the
practicing physician – facilitates diagnosis and allows the application of sound strategies
for management.The window of opportunity for aggressive control of all the traditional risk
factors for cardiovascular events or sudden death with intensiﬁcation of therapy is with
short duration diabetes, the absence of cardiovascular disease, and a history of severe
hypoglycemic events.To this list we can now add autonomic dysfunction and neuropathy,
which have become the most powerful predictors of risk for mortality. It seems prudent
that practitioners should be encouraged to become familiar with this information and apply
risk stratiﬁcation in clinical practice. After all, how difﬁcult is it to ask patients “do you have
numb feet?” and to determine their heart rate variability – it could be lifesaving. Ultimately
methods to reset the hypothalamus and the inﬂammatory cascade are needed if we are
to impact the care of patients with this compendium of conditions.
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My mind sent a message to my hypothalamus, told it to release the
hormoneCRFintotheshortvesselsconnectingmyhypothalamusand
mypituitarygland.TheCRFinspiredmypituitaryglandtodumpthe
hormoneACTHintomybloodstream.Mypituitaryhadbeenmaking
and storing ACTH for just such an occasion, and nearer and nearer
thezeppelincame.AndsomeoftheACTHinmybloodstreamreached
theoutershellofmyadrenalgland,whichhadbeenMyadrenalgland
added the glucocorticoids to my bloodstream. They went all over my
body, changing glycogen into glucose. Glucose was muscle food. It
would help me ﬁght like a wildcat or run like a deer.
KurtVonnegut,Jr., Breakfast of Champions,1973
THE LINK BETWEEN AUTONOMIC FUNCTION AND
INFLAMMATION
There has been an increasing shift to consider that inﬂammation
is central to the pathogenesis of diabetes and its complications
including macrovascular disease and microvascular disease, but
the origin for the inﬂammation has not been clearly delineated.
While inﬂammation can cause extensive tissue damage and death
it is also essential in the protection of the host and is a defense
mechanism against trauma, infection, and stress amongst other
provocative agents. What controls this response to trauma and
infection has been the focus of energetic pursuits over the past
decade and has revealed a potential answer. The inﬂammatory
response is controlled by neural circuitry of the autonomic ner-
vous system. The afferent arc consists of nerves that sense the
injury and infection and this in turn activates a cholinergic anti-
inﬂammatory pathway that modulates the response and is the
potential target for future therapies of diabetes (Borovikova et al.,
2000; Tracey, 2009). The lymphoid organs of the immune system
are innervated by cholinergic, catecholaminergic, dopaminergic,
and peptidergic neurons and the neurotransmitters can interact
withimmunecellsandaltertheirlevelof function.Forinstancein
the non-obese diabetic (NOD) mouse (as animal model for type
1 diabetes) neurons surrounding the pancreatic beta cells are lost
before there is damage to the islet,and the loss of tonic inhibitory
signals contributes to the subsequent beta cell destruction (Sar-
avia and Homo-Delarche, 2003). In addition destruction of the
capsaicinsensitivenerveﬁbersof thepancreasprotectthebetacell
from streptozotocin induced beta cell injury (Capsaicin and STZ;
Razavi et al., 2006). Thus it seems that to begin to understand the
role of the autonomic nervous system in its more complex role in
inﬂammation and autoimmunity one needs to delve further into
this complexity. Like St Thomas we need to probe deeper!
SYMPATHETIC AND PARASYMPATHETIC NERVOUS
SYSTEMS
Traditionally the organization of the physiologic control of auto-
nomic nervous system functions has relied upon the division into
twomainbranches,thesympatheticandparasympatheticnervous
systems (PNS). Stimulation of the sympathetic Brauch mediates
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physiologic responses of ﬁght and ﬂight that are manifest as
increasesinheartrate(HR)andbloodpressure(BP),mobilization
ofneededenergystores,andheightenedarousal.Themajorneuro-
transmitters are epinephrine,norepinephrine,and dopamine and
these neurotransmitters mediate cellular responses by interacting
with G-protein coupled adrenergic receptors (a1, a2, b1, b2, b3)
anddopaminergicreceptors(D1,D2,D3).Incontraststimulation
of the PNS tends to produce effects which are in general opposite
to those of the sympathetic nervous system (SNS) such as slowing
of the HR,decreased cardiac contractility,and enhanced digestive
functions. The principal neurotransmitter acetylcholine interacts
with G-protein coupled muscarinic acetylcholine receptors M1–
M5 and nicotinic ligand–gated ion channels (termed neuronal
type 1-111 and muscle type 1V; Wess et al., 2007).
Inaddition,thesystemsaredistinguishedbyuniqueanatomical
features.Parasympatheticneuronsresideinthebrainstemmedulla
and sacral portions of the spinal cord and sympathetic neuronal
cell bodies in the thoracic and lumbar spinal cord. Presynaptic
myelinated axons are projected through cranial nerves and/or
spinal nerves to synapses located in ganglia. From these postsy-
naptic unmyelinated ﬁbers are derived, which themselves target
the innervated organ. It is also important to realize that although
at ﬁrst glance these systems appear to have opposing effects, e.g.,
sympathetic increases HR and parasympathetic slows HR, stim-
ulation of both results in a greater increase in cardiac output
because sympathetic stimulation increases the ejection fraction
and parasympathetic stimulation slows the heart, thus allow-
ing increased efﬁciency of cardiac ﬁlling. Similarly, baroreceptors
which perceive stretch in the aorta with increasing BP send sig-
nals via the sensory component of the vagus terminating in the
nucleus of the tractus solitarius in the medulla. From here presy-
naptic ﬁbers of the SNS project to the ventrolateral nucleus of
the medulla and parasympathetic presynaptic neurons to nucleus
ambiguous in the medulla. Coordinated ﬁring of both arms of
the autonomic nervous system is necessary to respond to changes
in BP and, if damage occurs, is reset to accommodate new levels
which may be too high or too low for the individual. Thus, one
needs to consider the system in its entirety. Damage to one or
another component may not have as devastating an effect as dam-
agetothewholesystem.WithinthisframeworkFigure1illustrates
the entire workings of the autonomic nervous system.
AUTONOMIC NERVOUS SYSTEM CONTROL OF
INFLAMMATION
Watkins et al. (1995) discovered that sensory neurons detect the
presenceof inﬂammationintissues(Figure2).Theseresponsesto
IL-1inducedinﬂammationweremediatedbythevagus,andcould
be abolished by vagotomy or a selective competitive antagonist of
the IL-1 receptor (Goehler et al., 1997; Hansen et al., 2001). In
cardiovascular physiology,oxygen,glucose,and other metabolites
are sensed by specialized glomus cells in the association with the
nervoussystem.Uponactivation,thesecellsreleasedopamineand
norepinephrinecausingdepolarizationof thesensoryﬁbersinthe
vaguswhichpropagatetothebrainstemandinitiateamotoreffer-
ent arc. It appears that IL-1 binds to the glomus cells initiating the
afferent arc; however there are a number of other ligands derived
from macrophages, monocytes, and dendritic cells referred to as
pathogen-associated molecular patterns (PAMPS) which activate
Toll-like receptors (TLR) and lead to increased expression of NF-
kBandincreasedreleaseof inﬂammatorycytokinessuchasTNF-a
and IL-6. Endogenous molecular products are also released from
damaged cells and are referred to as damage associated molecular
patterns (DAMPS). Thus the nervous system is capable of initiat-
ing a response to tissue injury and inﬂammation and can per se
initiate a pro-inﬂammatory response. One must therefore add a
neuro-regulatory role for the autonomic nervous system to the
one outlined above.
The efferent arc of this inﬂammatory response is termed
thecholinergicanti-inﬂammatorypathway.Theneurotransmitter
acetylcholine interacts with the innate immune cells that express
the nicotinic acetylcholine receptor subunit a7 (a7nAChR). The
receptor is widely expressed in neurons which function as ligand-
gated ion channels encoded by CHRNA 7 on chromosome 15q14
and is a product of 10 exons yielding a mature protein of 50kDa.
a7nAChR has a tonic inhibitory role in the immune cells simi-
lar to the effects of the parasympathetic system on inhibition of
HR. Exaggerated responses to inﬂammatory molecules are caused
by vagotomy, whereas stimulation of the vagus downregulates
the production of TNFa, IL-1, IL-6, and IL-8but does not alter
the anti-inﬂammatory cytokine IL-10 and TGFb. This ACh acti-
vatestheJAK/STATpathway,affectingtheinﬂammatoryresponses
mediatedbyNF-kBandinitiatingthereleaseofavarietyofinﬂam-
matory cytokines. Thus this is a defensive reﬂex protecting the
organism from organ damage and death when exposed to syn-
dromes of excess cytokine release such as infection, trauma, and
stress.
DIABETES – A STATE OF FAULTY SYMPATHETIC BALANCE
AND CHRONIC INFLAMMATION
Wehavehypothesizedthatinthemetabolicsyndromeanddiabetes
there is a constant increase in low grade inﬂammation mediated
by a large cadre of exogenous and endogenous ligands (Figure3).
These in turn are capable of binding to the advanced glycation
endproductreceptor(RAGE)andtherebyactivatingNF-kBpath-
way and increasing the production of inﬂammatory cytokines. In
addition there are a number of other ligands capable of activat-
ing the inﬂammatory cascade. DAMPS for example,can stimulate
innateimmuneresponsesculminatinginNF-kBactivationaswith
the ligands for RAGE. This is further compounded by the ligands
binding to the TLR which potentiate the activation of NF-kB. The
balanceoccursbybindingofacetylcholinetothea7nACHRrecep-
torandviaJAK2andStatrestrainingtheactivationofNF-kB.Thus
the loss of autonomic control with reduction of parasympathetic
activity, hallmark autonomic dysfunction in diabetes, initiates a
cascade of inﬂammatory responses that, if continued unabated
will culminate in considerable morbidity and mortality. The pos-
sible approaches to enhancing parasympathetic function will be
discussed below.
THE CONSEQUENCE OF AUTONOMIC DYSFUNCTION IN
DIABETES
Cardiac autonomic neuropathy (CAN) and sympathetic/
parasympatheticimbalanceisasigniﬁcantcauseof morbidityand
mortality associated with a high risk of cardiac arrhythmias and
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FIGURE 1 |A diagrammatic illustration of the role of the two arms of the
autonomic nervous system. Note that in general the actions of the
sympathetic nervous system are illustrated as being in the opposite direction
to that of the parasympathetic nervous system. Not shown here but
discussed below is the CNS regulation of the immune system via the vagal
cholinergic anti-inﬂammatory pathway adding yet another dimension to the
role of the autonomic nervous system in survival of the organism. Note that
Kurt Vonnegut recognized the importance of the CNS in stress but failed to
recognize its role as the conductor of the endocrine and autonomic orchestra.
But then he was not a biologist!
sudden death, possibly related to silent myocardial ischemia. The
prevalence of CAN may be high. In a large cohort of patients with
T2DM,Ziegleretal.(1995),usingpredeﬁnedheartratevariability
(HRV)andspectralanalysisoftheR–Rintervals,foundthat34.3%
of those with T2DM had abnormal ﬁndings. Newly diagnosed
type 2 diabetes (Lieb et al., 2011) and prediabetes stages [(i.e.,
impaired glucose tolerance (IGT)] are associated with a decreased
parasympathetic modulation of the heart and a shift toward aug-
mented sympathetic tone. Factors that inﬂuence the prevalence
of CAN include the diagnostic criteria used, patient age, and the
duration of diabetes (Vinik and Ziegler,2007). Additional clinical
correlates and predictors of CAN include glycemic control; pres-
ence of distal peripheral neuropathy (DPN), nephropathy, and
retinopathy; BP levels, obesity; smoking; cholesterol; and triglyc-
erides levels (Vinik and Ziegler, 2007). Additional factors which
emergedasidentifyingsusceptibilitytocardiovasculareventswith
intensiﬁcation of glycemic control included: duration of diabetes
>12–15years, impaired renal function, coronary artery calciﬁca-
tion, a previous cardiovascular event, being African American,
being female, aging, a history of neuropathy or numb feet, and
loss in HRV (Calles-Escandon et al., 2010; Pop-Busui et al., 2010;
Viniketal.,2011).Parasympathetictonemaydeclinewithanauto-
nomic imbalance shifting toward augmented sympathetic tone
during the development from normal glucose tolerance to IGT
and ﬁnally diabetes (Wu et al., 2007).
MORBIDITY AND MORTALITY IN CARDIAC AUTONOMIC
NEUROPATHY
Cardiac autonomic neuropathy deﬁned by measures of abnor-
malities in PNS and SNS, is a signiﬁcant cause of morbidity
and mortality associated with a high risk of cardiac arrhythmias
and sudden death, possibly related to silent myocardial ischemia.
Cardiovascular disease (CVD) remains the main cause of excess
mortality among patients with type1 (T1DM) and type 2 dia-
betes (T2DM). The prevalence of CAN varies greatly depending
on the criteria used to identify CAN as well as the population
studied. These range from as low as 2.5% of the primary pre-
vention cohort in the Diabetes Control and Complications Trial
(DCCT, 1998) to as high as 90% of patients with long-standing
T1DM who were potential candidates for a pancreas transplant
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FIGURE 2 |Afferent sensory signals are transmitted by the vagus to the
nucleus of the solitary tract (NTS) and polysynaptic receptors relay to
the sympathetic via the rostral ventromedullary nucleus (RVLS) and the
parasympathetic nucleus ambiguous (NA and the dorsal vagal nucleus.
There is both sympathetic and parasympathetic output to the celiac ganglion
and the splenic nerve activates the inﬂammatory cascade in macrophages
which may be in the spleen but occur diffusely throughout the body.
Stimulation of the vagus inhibits this activation by acetylcholine binding to the
a7nACHR receptor which curtails the response. Also shown is the
coactivation of the hypothalamic pituitary axis with release of glucocorticoids
which also modulate the inﬂammatory response. It is however unclear how
this set point is determined in the body but what is clear is that autonomic
modulation of inﬂammation can be achieved by altering
sympathetic/parasympathetic balance.
(Kennedyetal.,1995).InalargecohortofpatientswithT1DMand
T2DM, Ziegler et al. (1995), using predeﬁned HRV and spectral
analysis of the R–R intervals, found that 25.3% of patients with
T1DM and 34.3% of those with T2DM had abnormal ﬁndings.
Eventheprediabeticstage(i.e.,IGT)isassociatedwithadecreased
parasympathetic modulation of the heart and a shift toward aug-
mentedsympathetictone.Parasympathetictonemaydeclinewith
an autonomic imbalance shifting toward augmented sympathetic
tone during the development from normal glucose tolerance to
IGT and ﬁnally diabetes (Wu et al., 2007). Reduced HRV as a
marker of autonomic dysfunction has been shown to have dire
consequencesintermsof morbidity(e.g.,progressionof coronary
atherosclerosis; Huikuri et al., 1999), and mortality independent
of cardiovascular risk factors (La Rovere et al., 2003; Maser et al.,
2003; Hadase et al., 2004; Janszky et al., 2004) in various popula-
tions including those with prediabetes and diabetes (Ziegler et al.,
2008; Beijers et al., 2009). In T1DM there is a fourfold increased
riskof death(Orchardetal.,1996).CANissigniﬁcantlyassociated
withoverallmortality(Maseretal.,2003;Viniketal.,2010)andin
some – but not all – studies with morbidity such as silent myocar-
dial ischemia, coronary artery disease, stroke, diabetic nephropa-
thy progression, and perioperative morbidity. Some pathogenetic
mechanismsmaylinkCANtocardiovasculardysfunctionanddia-
betic complications (Vinik et al., 2011). Thus, CAN assessment
may be used for cardiovascular risk stratiﬁcation in patients with
and without established CVD; as a marker for patients requiring
more intensive monitoring during the perioperative period and
other physiological stresses; and as an indicator for more inten-
sive pharmacotherapeutic and lifestyle management of comorbid
conditions.Clearlytheroleofautonomicimbalanceandthemech-
anisms underlying the risk require further exploration if we are to
achieve beneﬁt for all. However foremost in our minds is the issue
of why diagnose if we cannot treat?
CONSEQUENCES OF AGE/RAGE INTERACTIONS IN DIABETES
Hyperglycemia increases protein glycation and causes a gradual
accumulationof advancedglycationendproducts(AGEs)inbody
tissues. These AGEs form on intra- and extra-cellular proteins,
lipids, and nucleic acids, in complex arrangements that lead to
cross-linking. It has also been shown that an accumulation of
AGEs in collagen tissue such as skin, measured by skin autoﬂu-
orescence, correlates with severity of peripheral and autonomic
nerve abnormalities in diabetes,even before being clinically man-
ifest (Meerwaldt et al., 2005). Both immunohistochemical and
biochemicalstudieshaveshownthatcarboxymethyllysine(CML)-
modiﬁed proteins are AGEs that accumulate in tissues affected by
diabetic complications, such as bone. This process is mediated
through RAGE, the pattern recognition receptor for AGE. Of the
three known receptors for AGE, RAGE is of particular interest
because it is found on many cell types, especially those affected
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FIGURE 3 |The relationship between binding of ligands to the pattern
recognitionAGE receptor (RAGE) and inﬂammation, gene expression,
oxidative and nitrosative stress, and damage to the macro- and
microvasculature. Elevated levels of glucose bind to proteins and form
AGEs, which bind to RAGEs. RAGE signaling activates NADPH oxidase and
production of reactive oxygen species (ROS). Increased ROS increases
advanced oxidation protein products (AOPPs), more AGEs, and
AGE-modiﬁcation of oxidized LDLs (oxLDLs). Furthermore, increased ROS
may deplete glutathione, thereby suppressing glyoxalase I activity, a
mechanism favoring further AGE accumulation. AGEs, AOPPs, macrophage
glycoprotein (MAC-1), and AGE-oxLDL ligands of RAGE sustain stimulation of
RAGE, and these processes, together with increased ROS, activate key
transcription factors such as nuclear factor-kB (NF-kB) and Egr-1, which
increase gene transcription factors and activate inﬂammatory mechanisms.
Consequences include increased migration and activation of RAGE-expressing
neutrophils, monocytes/macrophages,T-cells, and dendritic cells.This results
in the release of the pro-inﬂammatory RAGE ligands S100/calgranulins and
high-mobility group protein box-1 (HMGB1). In this inﬂammatory
environment, further AGEs may be formed as well. Via interaction with RAGE,
these ligands magnify activation of NF-kB, Agr-1, and other factors, thereby
amplifying cellular stress and tissue damage leading to neurovascular
dysfunction. Soluble RAGE (sRAGE) is formed from the cleavage of RAGE by
disintegrins such as ADAM 10, a metalloproteinase, and b- and g-secretases.
sRAGE or a spliced variant (esRAGE) compete for binding of ligands to RAGE,
and a deﬁciency could theoretically initiate the sequence of events activating
an inﬂammatory cascade with an increase in the expression of
pro-inﬂammatory cytokines [E-selectin, endothelin-1 tissue factor, vascular
endothelial growth factor, and other pro-inﬂammatory cytokines (interleukin-6
and tumor necrosis factor-a)] and damage to neurons, kidney, eye, the
vasculature, and even bone. Increasing sRAGE or its administration could
competitively reduce activation of the AGE/RAGE pathway and it
consequences. In addition endogenous and exogenous ligands bind toToll-like
receptors (TLR) also targeting NF-KB as well as inducing the secretion of
pro-inﬂammatory cytokines which activate afferent sensory neurons reaching
the brainstem via axons in the vagus.This in turn activates the cholinergic
anti-inﬂammatory efferent arc which inhibits response in cytokine producing
immune cells and signal through the nicotinic acetylcholine receptor subunit
a7 (a7nACHR).This in turn inhibits NF-kB activation.Thus the pathways of
AGE/RAGE activation of the inﬂammatory cascade and the inﬂammatory
ligands target activation of an inﬂammatory cascade that can be abrogated by
either competing with the binding of ligands to RAGE or by vagal activation of
the anti-inﬂammatory reﬂex.Thus central to curtailing unbridled activation of
the inﬂammatory cascade is the integrity of parasympathetic autonomic
function or balance between the two arms of the autonomic nervous system.
by diabetes. RAGE is constitutively expressed but is also induced
by reactions known to initiate inﬂammation. Patients with dia-
betes often display elevated CML levels that can bind and activate
RAGE signaling (Schmidt et al., 2001). Furthermore, AGE-RAGE
interaction creates a chronic cascade of inﬂammation and tissue
injury. Of further interest, RAGE knockout mice have a reduced
capacity to develop neuropathy (Toth et al., 2008; Takuma et al.,
2009), and the soluble form of the AGE receptor sRAGE, can act
as a decoy molecule, thereby reducing the binding of ligands to
RAGE and inhibiting the inﬂammatory cascade (Figure 3). Our
studies in Charcot neuroarthropathy show the presence of severe
somatic and autonomic neuropathy in association with reduced
levels of sRAGE (Witzke et al., 2011) (Table 1).
Inhomeostasis,RAGEisexpressedatlowlevelsbutduringbio-
logical stresses such as inﬂammation and diabetes, RAGE expres-
sion is greatly upregulated as a direct result of AGE accumulation.
Many studies have now shown that AGE-RAGE interactions alter
intracellular signaling via pro-inﬂammatory cytokines such as
IL-6,TNF-a,andfreeradicalsthatfurtherpropagatediabeticcom-
plications. Interestingly the two pathways, autonomic function
and inﬂammation may be linked since it has become evident that
autonomicdysfunctionisassociatedwithanincreaseincirculating
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Table 1 | Peripheral and autonomic nerve dysfunction and reduction of sRAGE in diabetes and Charcot neuroarthropathy (mean  SD).
Control (n D30) Diabetes (n D30) Charcot (n D20)
Tibia-ankle
Amplitude 8.94.1 4.33.8* 0.61.0
†
Latency 4.70.7 4.21.8 3.65.5
Conduction velocity 45.43.7 35.415.2* 7 .713.1
†
F-wave 54.76.4 47 .523.3 17 .529.7
†
Sural Response (number with positive response) 30 28 4
Vibration perception (m) 10.611.1 31.727 .3* 100.531.5
†
Pressure perception (g) 2.90.4 3.10.3 5.91.2
†
Cold sensation (ºC) 5.52.7 7 .75.2 20.99.9
†
Warm sensation (ºC) 7 .13.1 10.33.2* 14.93.2
†
Cold pain 24.59.0 26.46.6 30.63.5
†
Warm pain 14.03.3 15.42.5* 17 .51.0
†
Valsalva ratio 1.430.25 1.360.31 1.180.28
†
Parasympathetic deep breathing 61113 61713 63218
†
Sympathetic Valsalva response 71417 71316 71720
N telopeptide (NTx; nmol/L) 13.65.5 11.45.7 13.88.2
Osteocalcin (ng/mL) 1.290.96 1.235.7 2.292.57*
sRAGE (pg/mL) 1140471 522660
‡
16267*
Bone mass density (BMD; g/cm2)
Femoral neck 1.0040.141 1.0480.184
‡
0.9040.219
Greater trochanter 1.0800.157 1.1160.165
‡
0.9870.185
Total hip 1.0180.129 1.0370.150 0.9550.252
Foot 0.7540.081 0.7920.105 0.7880.120
Calcaneal stiffness index 105.214.0 103.318.6 77 .126.2*
Continuous data are expressed as mean  SD; categoric data as n. *p<0.05 vs control subjects.
†p<0.05 vs diabetic and control subjects.
‡p<0.05 vs Charcot
subjects (Witzke et al., 2011) with permission.
inﬂammatory cytokines (Lieb et al., 2011). Furthermore, recent
studies support the notion that autonomic reﬂexes may control
the inﬂammatory response (Tracey, 2009).
CARDIOVASCULAR AUTONOMIC BALANCE
Autonomic balance involves complex interactions with several
physiologic mechanisms that act to maintain HR and BP within
normal limits. Recent investigations have suggested that auto-
nomic dysfunction (e.g., heightened activity of the SNS and sup-
pressed activity of the PNS) impairs the ability of the ANS to
regulate the cardiovascular system. Thus, autonomic imbalance
may be a key component involved in both the etiology and the
clinical course of CVD.What is also emerging is that one needs to
distinguishthedifferencebetweenautonomicimbalanceandclear
evidence of autonomic neuropathy. Autonomic imbalance pro-
duces a number of interesting and trying clinical situations such
as orthostatic tachycardia, orthostatic bradycardia, and hypoten-
sion and can be responsible for predisposition to arrhythmias and
sudden death (Vinik et al., 2011). The most interesting implica-
tion of loss of autonomic imbalance derives from the catastrophic
increase of sudden death in the ACCORD study with intensive
lowering of blood glucose in which the combination of numbness
of the feet and loss of HR variability increased the susceptibility
to an event with a risk ratio (RR) of 4.43 (Calles-Escandon et al.,
2010;Viniketal.,2011).MostrecentlyanInternationalGrouphas
updated deﬁnitions of diabetic neuropathy including autonomic
neuropathy and reported upon these (Tesfaye et al., 2010).
CARDIAC AUTONOMIC ASSESSMENT
Cardiovascular reﬂex tests are the gold standard in clinical auto-
nomic testing. These tests have good sensitivity, speciﬁcity, and
reproducibility and are non-invasive, safe, well-standardized, and
easily performed (Vinik and Ziegler,2007). The most widely used
tests assessing cardiac parasympathetic function are based on the
time-domain HR response to deep breathing, a Valsalva maneu-
ver, and postural change. However, a Valsalva maneuver must not
be performed in patients with proliferative retinopathy. Of these
tests, HR to deep breathing has the greatest speciﬁcity ( 80%).
Cardiovascular sympathetic function is assessed by measuring the
BP response to orthostatic change and a Valsalva maneuver. The
performance of these tests should be standardized, and the inﬂu-
enceof confoundingvariablessuchasmedications,hydration,and
antecedent activity should be minimized. Age normative values
should be used. The combination of cardiovascular autonomic
tests with sudomotor function tests may allow a more accurate
diagnosis of diabetic autonomic neuropathy (DAN), but this is
still in the research arena.
AnalysisofHRVisanon-invasiveelectrocardiographicmethod
for assessing overall autonomic activity (Malik and the Task Force
of the European Society of Cardiology and the North American
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Society of Pacing and Electrophysiology, 1996). Analysis of HRV,
withanalysisof respiratoryactivity,independentlyandsimultane-
ously measures parasympathetic and sympathetic activity (Aksel-
rod et al., 1981), and thereby provides information with regard
to autonomic balance of the cardiovascular system. Power spec-
tral analysis of HRV can be performed under resting conditions
with demonstration of low-frequency (LF) and high-frequency
(HF) components. The LF component of the power spectrum of
HRV primarily reﬂects sympathetic activity,while the HF compo-
nent(alsotermedtherespiratory-frequency,RF)primarilyreﬂects
parasympatheticactivity.LF/RFratiosarecalculatedandprovidea
measure of sympathetic/parasympathetic activity. The total spec-
tral power (TSP) is calculated, as are the standard deviation of
all normal R–R intervals (sdNN; a measure of both sympathetic
and parasympathetic action on HRV) and the root-mean square
of the difference of successive R–R intervals (rmSSD), a measure
primarily of parasympathetic activity (Vinik and Ziegler, 2007).
Diabetic patients with features of cardiac autonomic dysfunc-
tionsuchasunexplainedtachycardia,orthostatichypotension,and
poor exercise tolerance, or with other symptoms of autonomic
dysfunction should be evaluated for the presence of autonomic
dysfunction. Screening for autonomic dysfunction should be per-
formed at the diagnosis of type 2 diabetes and 5years after the
diagnosis of type 1 diabetes, particularly in patients at greater
risk due to a history of poor glycemic control, cardiovascular risk
factors,DPN,andmacro-ormicroangiopathicdiabeticcomplica-
tions. While a number of tests for autonomic dysfunction are in
the research arena some have been shown to be sufﬁciently robust
to be incorporated into routine clinical care (Tesfaye et al., 2010;
Spallone et al., 2011) (Table 2).
CAN TESTING FOR CLINICAL TRIALS AND RESEARCH
Thetime-domainHRtestsandtheBPresponsetoposturalchange
have the reproducibility necessary for clinical trials. These tests
wereusedasendpointsintheDiabetesControlandComplications
Trial/Epidemiology of Diabetes Interventions and Complications
Study (DCCT EDIC Research Group, 2005) and other clinical
trials.
Frequency-domainindicesobtainedbyapplyingspectralanaly-
sis to HR variability of short (5–7min) and long (24-h) elec-
trocardiogram recordings provide a measure of sympathetic and
parasympatheticmodulationof HRasdescribedbefore.HRspec-
tralpowerintheHFregionisameasureof parasympatheticmod-
ulation, while spectral power in the LF region provides a measure
of bothsympatheticandparasympatheticmodulation.TheLFBP
variability may provide a measure of sympathetic modulation. To
correctlyassessthesigniﬁcanceofthedifferentregions,respiration
should be measured or controlled breathing performed. These
methods, which need standardization, have been widely used in
research and as end points in clinical trials. These have now been
showntobeinvaluableinpatientswithclinicalsyndromesofauto-
nomic excess or deﬁciency and can be accomplished in 15min at
the bedside without need to resort to more complex studies using
tilt table testing,for example. In addition it is a sound general rule
that an autonomic function test becomes useful when suspecting
autonomic nerve dysfunction (gastroparesis, erectile dysfunction
or diabetic diarrhea, and syncope amongst other conditions). A
negative test has >95% negative predictive value for autonomic
dysfunction and becomes the relatively simple surrogate for more
expensive, complex, and at times invasive tests (Figure 4).
TREATMENT OF AUTONOMIC DYSFUNCTION
TARGETING INFLAMMATION
Thetreatmentof inﬂammatorydiseasesincludingchronicinﬂam-
matory demyelinating polyneuropathy (CIDP) and autonomic
neuropathyhashadasigniﬁcantboostbytheuseof immunoglob-
ulin, and biological agents that modulate the activity of TNF-a,
IL-1, and IL-6 (Pittenger et al., 1997; Vinik et al., 2006b; Ananda-
coomaraswamyetal.,2008;BourcierandVinik,2010;Handelsman
etal.,2011).Theseagentshavebeenshowntoamelioraterheuma-
toid arthritis and inﬂammatory bowel disease, which is what
serendipitously directed us to the use of an anti-TNFa in dia-
betic neuropathies. They are,however,potentially harmful as they
areimmunosuppressantsandamorebenigninterventionisclearly
necessary.Forexample,electricalstimulationofthevagusnerveor
administration of the a7nACHR agonists reduces the magnitude
FIGURE 4 | Spectral analysis of heart rate variability.
Table 2 | Cardiovascular autonomic tests and suggested indications for their use.
Clinical diagnosis Research end point Clinical trials
HR cardiovascular tests Yes Yes Yes
Orthostatic hypotension test Yes Yes No (low sensitivity)
QT interval Yes (additional information and risk stratiﬁcation) Yes No (low sensitivity)
ABPM for dipping status Yes (risk stratiﬁcation) Yes No (low sensitivity)
HRV time- and frequency-domain indices Yes (early additional information and risk stratiﬁcation) Yes Yes
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of the inﬂammatory response by 50–75% without compromising
cytokineactivity(Borovikovaetal.,2000;Berniketal.,2002;Saeed
etal.,2005;Hustonetal.,2006).Depressedvagalactivityortheloss
of sympathovagal balance has been shown to cause exaggerated
pro-inﬂammatory responses and increased morbidity and mor-
tality (Thayer and Sternberg, 2006; Thayer and Fischer, 2009).
Vagus nerve activity can be measured in humans by time and
frequency-domain analysis of instantaneous HRV in the resting
stateaswellaswithprovocativetestingof theeffectsof vagalstim-
ulationusingtherespiratoryvariation,theValsalvamaneuver,and
the effects of standing (Vinik and Ziegler, 2007). Also, peripheral
vagal activity can be measured using the pancreatic polypeptide
response to insulin hypoglycemia or beef meals (Glaser et al.,
1980), and peripheral preganglionic measures of acetylcholine
effects on sweating can be determined using sudorimetry, and
quantitative sudorimetry (Low et al., 1983; Vinik and Ziegler,
2007).
Indeed in our studies of the regulation of skin blood ﬂow we
have shown that there are major differences in the autonomic
regulation of blood ﬂow in hairy skin of the forearm, which is
almost entirely dependent on sympathetic/parasympathetic con-
trol (Vinik et al., 2006a). By contrast in glabrous skin there is a
dependence on vasodilatory peptides such as CGRP and Neu-
rokinin A as well as certain vasodilatory and vasoconstrictive
prostaglandins (Vinik and Kles, 2006). In rheumatoid arthri-
tis high-frequency oscillation which reﬂect vagal activity are
depressed compared with healthy controls (Pontet et al., 2003).
Pontet and colleagues evaluated the effects of HRV on the crit-
ical care setting in patients with sepsis a low HRV is associated
with organ failure whereas subjects with a normal HRV had
uneventful hospital stays (Pontet et al., 2003). The mortality rate
of individuals with low HRV on admission was 63.6% com-
pared with 0% in the group with normal HRV (Pontet et al.,
2003). Of greater interest is the association between atheroma
and reduced HRV (Hanson and Libby, 2006; von Kanel et al.,
2008).
THERAPEUTIC IMPLICATIONS OF ALTERING AUTONOMIC BALANCE
We (Lieb et al., 2011) examined patients with newly diagnosed
diabetes,established diabetes,and healthy controls and analyzed a
cadreof inﬂammatorymarkersinadditiontotimeandfrequency-
domain measures of autonomic function. Of great interest to us is
the appearance before the advent of inﬂammation of loss of HRV
as well as loss of sympathetic/parasympathetic balance (Figure 5;
Table3).Earlyinthedevelopmentofautonomicdysfunctionthere
is loss of HRV and this correlates with an increase in circulating
markers of inﬂammation such as CRP and IL-6 (Lieb et al.,2011).
Analysis of 102 healthy middle aged individuals found an
association between loss in HRV and IL-6 levels. The authors
concluded that low grade inﬂammation is associated with loss
in HRV (von Kanel et al., 2008). Another study on 611 healthy
adults showed an inverse correlation between HRV and CRP lev-
els.Theauthorsconcludedthattheeffectcouldbeattributedtolow
grade inﬂammation due to a decrease in the cholinergic pathway
of anti-inﬂammatory cascades with implications for addressing
inﬂammation in the prevention and management of heart dis-
eases (Thayer and Fischer, 2009). HRV, CRP, and IL-6 levels were
measured in 757 young adults and HRV was signiﬁcantly related
to IL-6 and CRP levels which was thought to be consistent with
the notion that the cholinergic anti-inﬂammatory pathways exert
a tonic inhibitory inﬂuence on innate immune responses and
couldbethepotentialtargetforfutureinterventions.Of particular
note is the sequence of events shown in Figure 5 suggesting that
circulatingadiponectin(HMW)andleptinlevelsmaybeearlypre-
dictive markers, and the mechanism may be via insulin resistance
ordirectactionsofLeptinonthehypothalamusandtheautonomic
nervous system. In our study,we found that newly diagnosed dia-
betic subjects had signiﬁcantly lower HMW adiponectin/leptin
ratios when compared with control subjects, and saw signiﬁcant
correlations between the HMWA/leptin ratio and multiple mea-
sures of autonomic function (LFa/RFa ratio, TSP baseline, and
rmSSD baseline) (Lieb et al., 2011). In a study of 120 non-obese
humans without diabetes, Paolisso et al. (2000) demonstrated
FIGURE 5 |The natural history of autonomic balance.
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Table 3 | Measures of autonomic function and inﬂammation in healthy controls, newly diagnosed and established diabetes.
Measure Controls (n D15) Newly diagnosedT2D (n D15) EstablishedT2D (n D15) p value
R–R ratio (deep breathing) 1.260.04 1.200.03 1.170.05 0.0325#
R–R ratio (Valsalva) 1.580.21 1.370.06 1.240.05 0.0270*
R–R ratio (standing) 1.290.04 1.260.05 1.180.02 NS
LFa 1.600.43 1.900.39 1.370.37 NS
RFa 1.210.27 1.890.79 0.730.29 NS
LFa/RFa ratio 1.530.24 2.510.51 2.880.56 NS
TSP baseline 950.88191.95 772.94290.95 416.95142.61 0.0023*
sdNN baseline 47 .664.87 41.043.92 28.924.65 0.0008*
rmSSD baseline 30.183.76 28.776.97 18.973.38 0.0356#
IL -6 (pg/mL) 2.840.68 (nD14) 11.582.83 12.041.20 (nD12) <0.0001#
TNF-a (pg/mL) 9.322.18 (nD14) 9.141.15 27 .9315.4 (nD12) NS
PAI-1 (ng/mL) 3.050.56 5.230.76 6.411.36 0.0305*
Total adiponectin (mg/mL) 6.760.78 7 .481.11 8.912.3 NS
High-molecular weight adiponectin (mg/mL) 1.780.26 2.330.60 2.711.54 NS
Leptin (ng/mL) 28.667 .93 46.877 .96 55.9311.39 NS
TA/L ratio 1.170.76 0.240.05 0.530.32 0.0340*
HMWA/L ratio 0.490.40 0.070.02 0.260.22 0.0442#
Modiﬁed from Lieb et al. (2011).
Data are presented as means  SE. NS, not signiﬁcant. *EstablishedT2D vs controls/newly diagnosedT2D.
#Newly diagnosed/establishedT2D vs controls.
TSP , total spectral power; SDNN, standard deviation of all normal R–R intervals; rmSSD, root-mean square of the difference of successive R–R intervals.
IL-6, interleukin-6; TNFa, tumor necrosis factor alpha; PAI, plasminogen activator Inhibitor 1; TA/L, total adiponectin/leptin ratio; HMWA/L, high-molecular weight
adiponectin/leptin ratio.
that increasing plasma leptin concentrations were associated with
increasingLFa/HFaratios,suggestinggreaterSNSactivityascom-
pared with PSN activity. Studies have also shown interesting
correlations between adiponectin and autonomic function. Wak-
abayashi and Aso (2004) studied 105 men and women with T2D
and found that adiponectin concentrations correlated negatively
withtheLFa/RFaratio.Of note,changesintheadiponectin/leptin
balance in the course of diabetes may ﬁrst be seen by utilizing
measures of high-molecular weight adiponectin rather than total
adiponectin, as demonstrated by our ﬁndings (Table 3). These
ﬁndings and the results in animal studies again suggest that the
effects on adipose tissue cytokine release may be a consequence
of autonomic dysfunction as opposed to the corollary. Clearly a
closer look at the relationship between adipose tissue cytokines,
obesity, and the impact of weight reduction on the relationship
between inﬂammation and HRV is warranted. With the explosive
developments in global obesity and the proliferation of gastric
bypass procedures on adults and even children, no doubt this
will yield a fertile ﬁeld for exploring these relationships and their
potential for therapeutic intervention.
RESTORING AUTONOMIC BALANCE
Physiological health is characterized by organized variability in
organ functions which are controlled by neural networks that
provide compensatory output to maintain homeostasis around
set points which are appropriate for the system in time, gender,
age, body weight, and BP among other variables such as exercise,
sedentaryhabits,andsmoking.Whiletheseneuralnetworkimbal-
ancescantheoreticallybecorrectedbyrelativelysimplemaneuvers
they are in general difﬁcult to obtain and maintain. However this
is possible. Our interest in falling and fractures in older diabet-
ics has taught us that much of these injuries are due to the loss
of the organized variability, strength, and reaction times; further-
more, with very simple strength and balance training falls risk
can be signiﬁcantly reduced (Morrison et al., 2010). Just as when
landingplanesinHongKongthepilotindulgesinserialdeviations
in wing tip position to allow the computer to correct these and
ensure a safe landing we have a need to enhance the imbalance in
autonomic and inﬂammatory reﬂexes that characterize the loss of
physiological and pathological ﬂexibility. Just as in diabetes man-
agement, this requires work and of course we all want the magic
bullet. Some are on the horizon. However,even simple maneuvers
suchaswalkingthedogcanrestoreautonomicbalance(Figure6).
For the abnormalities in autonomic balance adrenergic excess can
be addressed with beta blockers and parasympathetic excess with
anticholinergic drugs (Vinik and Erbas, 2006; Table 4).
REVERSIBILITY OF AUTONOMIC IMBALANCE
We have reported simple pharmacological manipulation of situa-
tions of parasympathetic and sympathetic imbalance with impor-
tant changes in the symptom complex and quality of life of the
afﬂicted individuals (Vinik et al., 2011). Intervention studies have
documented the protective effects of glycemic control in type 1
diabetes (DCCT) and of multifactorial strategy aimed at lifestyle
changewithpharmacologicalcorrectionof hyperglycemia,hyper-
tension,dyslipidemia,and microalbuminuria (Gaede et al.,2003).
ImmunetherapyforpatientswithantibodiestotheACHrecep-
tor has been effective in relieving postural hypotension (Bourcier
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FIGURE 6 |The effects of walking with and without a pet dog, on
parasympathetic function (mean high frequency power). (A) 80-min
walking programme including two 30-min walks without and with the dog
(n=13). (B) 80-min walking programme over three consecutive days (nD3).
(C) Interaction with the dog at home during 6h of continuous monitoring
(n=4).
Table 4 | Diagnosis and management of autonomic dysfunction.
Symptoms Assessment Modalities Management
Resting tachycardia, exercise intolerance, early
fatigue, and weakness with exercise
HRV, respiratory HRV, MUGA thallium
scan, 123I MIBG scan
Graded supervised exercise, beta blockers,
ACE-inhibitors
Postural hypotension, dizziness, lightheadedness,
weakness, fatigue, syncope, tachycardia/bradycardia
HRV, blood pressure measurement
lying, and standing
Mechanical measures, clonidine, midodrine,
octreotide, erythropoietin, pyridostigmine
Hyperhidrosis Sympathetic/parasympathetic balance Clonidine, amitryptylline, trihexyphenidyle,
propantheline, or scopolamine, botox, glycopyrrolate
and Vinik, 2010). Antioxidant therapy with alpha lipoic acid
restores autonomic function toward normal (Ziegler et al., 2011).
More recently interest in the selective muscarinic acetylcholine
receptor has been shown to suppress innate immune responses in
the periphery by increasing the ﬁring rate of action potential in
the vagus (Pavlov et al., 2007). To quote “The end products of a
searchforagentswithwhichtorestorebalancewillbeamapof the
homunculus of sensory and motor components corresponding to
neuroanatomical and functional neurophysiologic pathways link-
ingtheautonomicandinﬂammatorypathwaysandtheirresponse
toendogenousaswellasexogenousstressorsof thesystem.”While
Kurt Vonnegut had insights in Breakfast of Champions in 1973 it
is only now that this link is gaining recognition for the havoc
it wreaks and the potential for avoidance and therapeutic inter-
vention. Of great interest are the abnormalities in the diurnal
regulation of dopaminergic tone. In type 2 diabetes a reduction
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in dopaminergic tone in the early morning results in increased
hepatic gluconeogenesis, a rise in circulating free fatty acids,
resistance to the action of insulin, increases in markers of inﬂam-
mation and hypercoagulation,all of which can be restored toward
normality by treatment with a dopaminergic agonist (Scranton
et al.,2007) which reverses the metabolic abnormalities simply by
enhancing parasympathetic dominance. There are simple maneu-
verstoimproveHRVasshownbyMotookaetal.(2006).Littleold
ladies walking the dog have enhanced parasympathetic function.
Removingthedogisenoughtoincitesympatheticoveractivity.We
have shown that balance can be adjusted with agents that act on
one or other arm of the autonomic nervous system (Vinik et al.,
2011; Figure 7)
Gaede in the Steno memorial study (Gaede et al., 1999, 2008)
showed that a multifactorial intervention controlling BP, lipids,
and hyperglycemia reduces abnormalities in autonomic func-
tion by 68%, and Ziegler et al. (1997) report that alpha lipoic
acid improves autonomic function. In fact, it is one of the only
drugs targeting the nervous system to be endorsed by the Toronto
consensus (Tesfaye et al., 2010). In contrast failure to identify
loss of parasympathetic integrity is accompanied by dire conse-
quences as witnessed by the 22% increase in sudden death in the
ACCORD study with intensiﬁcation of therapy (Calles-Escandon
et al., 2010; Pop-Busui et al., 2010). Clearly this is discord rather
than accord.
CONCLUSION
There is now strong evidence of inﬂammation with activation of
inﬂammatory cytokines such as IL-6 and leptin in newly diag-
nosed type 2 diabetes. These changes correlate with abnormalities
in sympathetic-vagal balance. Autonomic dysfunction has been
shown to be a predictor of cardiovascular risk and sudden death
in patients with type 2 diabetes. A better understanding of the
autonomic dysfunction and adipose tissue inﬂammation seen
early in the development of diabetes will lead to further mea-
sures for determining which individuals are at the highest risk
for CVD and mortality, and will also lead to the development of
new therapies for reducing that risk. Activation of the efferent
arm of the reﬂex arc (through the administration of an acetyl-
choline receptor agonist) causes a decrease in pro-inﬂammatory
cytokine production, and a reduction in disease severity (Bernik
et al., 2002; Van Maanen et al., 2009). In his review Tracey (2009)
points out a number of important clinical studies that show cor-
relations between vagal nerve activity and inﬂammatory human
diseases such as rheumatoid arthritis and lupus. Our results are
in keeping with this research, and suggest that such a reﬂex arc
FIGURE 7 | Restoration of autonomic balance.
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may be involved in the inﬂammation seen early in T2D. How-
ever, our studies implicate the hypothalamus as the conductor
of the endocrine orchestra and show that the earliest changes
that are detectable in the evolution of diabetes are abnormalities
in autonomic balance (Figure 5). It is not beyond the realms
of reason that we could reverse the unfortunate evolutionary
proﬁle by targeting the hypothalamic set point of autonomic
balance.
REFERENCES
Akselrod, S., Gordon, D., Ubel, F. A.,
Shannon, D. C., Berger, A. C., and
Cohen,R.J.(1981).Powerspectrum
analysis of heart rate ﬂuctuation: a
quantitative probe of beat-to-beat
cardiovascular control. Science 213,
220–222.
Anandacoomaraswamy, D., Ullal, J.,
and Vinik, A. I. (2008). A 70-year-
old male with peripheral neuropa-
thy, ataxia and antigliadin antibod-
ies shows improvement, but not
ataxia, after intravenous immuno-
globin and gluten-free diet. J. Mul-
tidiscip. Healthc. 1, 93–96.
Beijers, H. J., Ferreira, I., Bravenboer,
B., Dekker, J. M., Nijpels, G., Heine,
R. J., and Stehouwer, C. D. (2009).
Microalbuminuriaandcardiovascu-
lar autonomic dysfunction are inde-
pendentlyassociatedwithcardiovas-
cularmortality:evidencefordistinct
pathways:theHoornStudy.Diabetes
Care 32, 1698–1703.
Bernik, T. R., Friedman, S. G., Ochani,
M., DiRaimo, R., Ulloa, L.,Yang, H.,
Sudan, S., Czura, C. J., Ivanova, S.
M.,andTracey,K.J.(2002).Pharma-
cological stimulation of the cholin-
ergic antiinﬂammatory pathway. J.
Exp. Med. 195, 781–788.
Borovikova, L. V., Ivanova, S., Zhang,
M., Yang, H., Botchkina, G. I.,
Watkins, L. R., Wang, H., Abum-
rad, N., Eaton, J. W., and Tracey, K.
J. (2000). Vagus nerve stimulation
attenuates the systemic inﬂamma-
tory response to endotoxin. Nature
405, 458–462.
Bourcier, M. E., and Vinik, A. I.
(2010). Case 1: a novel treatment
for pain in chronic inﬂammatory
demyelinating polyneuropathy. Pain
Medicine News 78–80. Available at:
www.painmedicinenews.com
Calles-Escandon,J.,Lovato,L.,Simons-
Morton, D., Kendall, D., Pop-Busui,
R.,Cohen,R.,Bonds,D.,Fonseca,V.,
Ismail-Beigi, F., Banerji, M., Failor,
A., and Hamilton, B. (2010). Effect
of intensive compared with stan-
dard glycemia treatment strategies
on mortality by baseline subgroup
characteristics. Diabetes Care 33,
721–727.
DCCT. (1998). The effect of inten-
sive diabetes therapy on measures of
autonomic nervous system function
intheDiabetesControlandCompli-
cations Trial (DCCT). Diabetologia
41, 416–423.
DCCT EDIC Research Group. (2005).
Intensive diabetes treatment and
cardiovascular disease in patients
with type 1 diabetes. N. Engl. J. Med.
353, 2643–2653.
Gaede, P., Lund-Andersen, H., Parv-
ing, H. H., and Pedersen, O. (2008).
Effect of a multifactorial interven-
tion on mortality in type 2 diabetes.
N. Engl. J. Med. 358, 580–591.
Gaede, P., Vedel, P., Larsen, N., Jensen,
G., Parving, H., and Pedersen,
O. (2003). Multifactorial interven-
tion and cardiovascular disease in
patients with type 2 diabetes. N.
Engl. J. Med. 348, 383–393.
Gaede, P., Vedel, P., Parving, H. H.,
and Pedersen, O. (1999). Intensi-
ﬁed multifactorial intervention in
patients with type 2 diabetes melli-
tusandmicroalbuminuria:theSteno
type 2 randomized study. Lancet
353, 617–622.
Glaser, B., Vinik, A. I., Sive, A. A., and
Floyd,J.C.Jr.(1980).Plasmahuman
pancreatic polypeptide responses to
administered secretin: effects of sur-
gical vagotomy, cholinergic block-
ade,andchronicpancreatitis.J.Clin.
Endocrinol. Metab. 50, 1094–1099.
Goehler, L. E., Relton, J. K., Dripps,
D., Kiechle, R., Tartaglia, N., Maier,
S. F., and Watkins, L. R. (1997).
Vagal paraganglia bind biotinylated
interleukin-1 receptor antagonist: a
possible mechanism for immune-
to-brain communication. Brain Res.
Bull. 43, 357–364.
Hadase, M., Azuma, A., Zen, K.,
Asada, S., Kawasaki, T., Kamitani,
T., Kawasaki, S., Sugihara, H., and
Matsubara, H. (2004). Very low fre-
quency power of heart rate vari-
ability is a powerful predictor of
clinical prognosis in patients with
congestive heart failure. Circ. J. 68,
343–347.
Handelsman, Y., Mechanick, J., Blond,
L.,Grunberger,G.,Bloomgarden,Z.,
Bray, G., Dagogo-Jack, S., Davidson,
J. A., Einhorn, D., Ganda, O., Gar-
ber, A. J., Hirsch, I. B., Horton, E.
S., Ismail-Beigi, F., Jellinger, P. S.,
Jones, K. L., Jovanovic, L., Lebovitz,
H., Levy, P., Moghissi, E. S., Orzeck,
E. A., Vinik, A. I., Wyne, K. L.,
and AACE Task Force for Develop-
ing Diabetes Comprehensive Care
Plan. (2011). American Association
of Clinical Endocrinologists Med-
ical Guidelines for Clinical Practice
for developing a diabetes mellitus
comprehensive care plan. Endocr.
Pract. 17, 1–53.
Hansen, M. K., O’Connor, K. A.,
Goehler, L. E., Watkins, L. R., and
Maier,S.F.(2001).Thecontribution
of the vagus nerve in interleukin-
1beta-inducedfeverisdependenton
dose. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 280, R929–R934.
Hanson,G.K.,andLibby,P.(2006).The
immune response in atherosclero-
sis: a double-edged sword. Nat. Rev.
Immunol. 6, 508–519.
Huikuri, H. V., Jokinen, V., Syvanne,
M., Nieminen, M. S., Airaksinen, K.
E., Ikaheimo, M. J., Koistinen, J. M.,
Kauma, H., Kesaniemi, A. Y., Maja-
halme, S., Niemelä, K. O., and Frick,
M. H. (1999). Heart rate variability
and progression of coronary athero-
sclerosis. Arterioscler. Thromb. Vasc.
Biol. 19, 1979–1985.
Huston, J. M., Ochani, M., Rosas-
Ballina, M., Liao, H., Ochani, K.,
Pavlov, V. A., Gallowitsch-Puerta,
M.,Ashok, M., Czura, C. J., Foxwell,
B., Tracey, K. J., and Ulloa, L.
(2006). Splenectomy inactivates the
cholinergic antiinﬂammatory path-
way during lethal endotoxemia and
polymicrobial sepsis. J. Exp. Med.
203, 1623–1628.
Janszky, I., Ericson, M., Mittleman,
M. A., Wamala, S., Al-Khalili, F.,
Schenck-Gustafsson, K., and Orth-
Gomer, K. (2004). Heart rate vari-
ability in long-term risk assess-
ment in middle-aged women with
coronary heart disease: the Stock-
holm Female Coronary Risk Study.
J. Intern. Med. 255, 13–21.
Kennedy,W.R.,Navarro,X.,andSuther-
land, D. E. (1995). Neuropathy pro-
ﬁle of diabetic patients in a pancreas
transplantation program. Neurology
45, 773–780.
La Rovere, M. T., Pinna, G. D., Maestri,
R., Mortara, A., Capomolla, S.,
Febo, O., Ferrari, R., Franchini, M.,
Gnemmi, M., Opasich, C., Riccardi,
P. G., Traversi, E., and Cobelli, F.
(2003). Short-term heart rate vari-
ability strongly predicts sudden car-
diac death in chronic heart failure
patients. Circulation 107, 565–570.
Lieb, D., Parson, H., Mamikunian, G.,
and Vinik, A. (2011). Cardiac auto-
nomic imbalance in newly diag-
nosed and established diabetes is
associated with markers of adipose
tissue inﬂammation. Exp. Diabetes
Res. 2012, 1–8.
Low, P. A., Caskey, P. E., Tuck, R. R.,
Fealey, R. D., and Dyck, P. J. (1983).
Quantitative sudomotor axon reﬂex
test in normal and neuropathic sub-
jects. Ann. Neurol. 14, 573–580.
Malik, M., and the Task Force of the
European Society of Cardiology and
the North American Society of Pac-
ing and Electrophysiology. (1996).
Heart rate variability, standards of
measurement, physiological inter-
pretation, and clinical use. Circula-
tion 93, 1043–1065.
Maser, R. E., Mitchell, B. D., Vinik,
A. I., and Freeman, R. (2003). The
association between cardiovascular
autonomic neuropathy and mor-
tality in individuals with diabetes:
a meta-analysis. Diabetes Care 26,
1895–1901.
Meerwaldt, R., Links, T. P., Graaff,
R., Hoogenberg, K., Lefrandt, J. D.,
Baynes, J. W., Gans, R. O., and
Smit, A. J. (2005). Increased accu-
mulation of skin advanced glyca-
tionend-productsprecedesandcor-
relates with clinical manifestation
of diabetic neuropathy. Diabetologia
48, 1637–1644.
Morrison, S., Colberg, S. R., Mariano,
M., Parson, H. K., and Vinik, A. I.
(2010).Balancetrainingreducesfalls
risk in older individuals with type 2
diabetes. Diabetes Care 33,748–750.
Motooka, M., Koike, H., Yokoyama, T.,
and Kennedy, N. L. (2006). Effect
of dog-walking on autonomic ner-
vous activity in senior citizens. Med.
J. Aust. 184, 60–63.
Orchard, T. J., Lloyd, C. E., Maser, R.
E., and Kuller, L. H. (1996). Why
does diabetic autonomic neuropa-
thy predict IDDM mortality? An
analysis from the Pittsburgh Epi-
demiology of Diabetes Complica-
tionsStudy.DiabetesRes.Clin.Pract.
34:S165-S171.
Paolisso, G., Manzella, D., Montano,
N., Gambardella, A., and Varric-
chio, M. (2000). Plasma leptin con-
centrations and cardiac autonomic
nervous system in healthy subjects
with different body weights. J. Clin.
Endocrinol. Metab. 85, 1810–1814.
Pavlov, V. A., Ochani, M., Yang,
L. H., Gallowitsch-Puerta, M.,
Ochani, K., Lin, X., Levi, J., Par-
rish, W. R., Rosas-Ballina, M.,
Czura, C. J., Larosa, G. J., Miller,
E. J., Tracey, K. J., and Al-Abed,
Y.(2007). Selective alpha7-nicotinic
acetylcholine receptor agonist
Frontiers in Endocrinology | Diabetes June 2012 | Volume 3 | Article 71 | 12Vinik Autonomic function
GTS-21improvessurvivalinmurine
endotoxemia and severe sepsis. Crit.
Care Med. 35, 1139–1144.
Pittenger, G. L., Liu, D., and Vinik,
A. I. (1997). The apoptotic death
of neuroblastoma cells caused by
serum from patients with insulin-
dependent diabetes and neuropathy
may be Fas-mediated. J. Neuroim-
munol. 76, 153–160.
Pontet, J., Contreras, P., Curbelo, A.,
Medina, J., Noveri, S., Bentancourt,
S., and Migliaro, E. R. (2003). Heart
rate variability as early marker of
multiple organ dysfunction syn-
dromeinsepticpatients.J.Crit.Care
18, 156–163.
Pop-Busui, R., Evans, G., Gerstein, H.,
Fonseca, V., Fleg, J., Hoogwerf, B.,
Genuth, S., Grimm, R., Corson, M.,
Prineas, R., and Action to Con-
trol Cardiovascular Risk in Dia-
betesStudyGroup.(2010).Effectsof
cardiac autonomic dysfunction on
mortality risk in the action to con-
trol cardiovascular risk in diabetes
(ACCORD) trial. Diabetes Care 33,
1578–1584.
Razavi, R., Chan, Y., Aﬁﬁyan, F. N.,
Liu, X. J., Wan, X., Yantha, J., Tsui,
H., Tang, L., Tsai, S., Santamaria,
P., Driver, J. P., Serreze, D., Salter,
M. W., and Dosch, H. M. (2006).
TRPV1 (sensory neurons control
beta cell stress and islet inﬂamma-
tion in autoimmune diabetes. Cell
127, 1123–1135.
Saeed,R.W.,Varma,S.,Peng-Nemeroff,
T., Sherry, B., Balakhaneh, D., Hus-
ton, J., Tracey, K. J., Al-Abed, Y.,
and Metz, C. N. (2005). Choliner-
gic stimulation blocks endothelial
cellactivationandleukocyterecruit-
ment during inﬂammation. J. Exp.
Med. 201, 1113–1123.
Saravia, F., and Homo-Delarche, F.
(2003). Is innervation an early tar-
get in autoimmune diabetes? Trends
Immunol. 24, 574–579.
Schmidt,A.M.,Yan,S.D.,Yan,S.F.,and
Stern,D.M.(2001).Themultiligand
receptor RAGE as a progression fac-
tor amplifying immune and inﬂam-
matoryresponses.J.Clin.Invest.108,
949–955.
Scranton, R. E., Gaziano, J. M.,
Rutty, D., Ezrokhi, M., and Cin-
cotta, A. (2007). A randomized,
double-blind, placebo-controlled
trial to assess safety and tolera-
bility during treatment of type
2 diabetes with usual diabetes
therapy and either Cycloset or
placebo. BMC Endocr. Disord. 7, 3.
doi:10.1186/1472-6823-7-3
Spallone, V., Ziegler, D., Freeman, R.,
Bernardi,L.,Frontoni,S.,Pop-Busui,
R., Stevens, M., Kempler, P., Hilsted,
J., Tesfaye, S., Low, P., Valensi, P.,
and On Behalf of the Toronto Con-
sensus Panel on Diabetic Neuropa-
thy. (2011). Cardiovascular auto-
nomic neuropathy in diabetes: clin-
ical impact, assessment, diagnosis,
and management. Diabetes Metab.
Res. Rev.
Takuma, K., Fang, F., Zhang, W., Yan,
S., Fukuzaki, E., Du, H., Sosunov,
A., McKhann, G., Funatsu, Y.,
Nakamichi,N.,Nagai,T.,Mizoguchi,
H., Ibi, D., Hori, O., Ogawa, S.,
Stern,D. M.,Yamada,K.,andYan,S.
S. (2009). RAGE-mediated signaling
contributes to intraneuronal trans-
port of amyloid-beta and neuronal
dysfunction. Proc. Natl. Acad. Sci.
U.S.A. 106, 20021–20026.
Tesfaye, S., Boulton, A. J., Dyck, P. J.,
Freeman, R., Horowitz, M., Kem-
pler, P., Lauria, G., Malik, R. A.,
Spallone, V., Vinik, A., Bernardi, L.,
Valensi, P., and Toronto Diabetic
Neuropathy Expert Group. (2010).
Diabetic neuropathies: update on
deﬁnitions, diagnostic criteria, esti-
mation of severity, and treatments.
Diabetes Care 33, 2285–2293.
Thayer, J. F., and Fischer, J. E. (2009).
Heart rate variability, overnight uri-
nary norepinephrine and C-reactive
protein: evidence for the choliner-
gic anti-inﬂammatory pathway in
healthyhumanadults.J.Intern.Med.
265, 439–447.
Thayer, J. F., and Sternberg, E. (2006).
Beyond heart rate variability: vagal
regulationof allostaticsystems.Ann.
N. Y. Acad. Sci. 1088, 361–372.
Toth, C., Rong, L. L., Yang, C.,
Martinez, J., Song, F., Ramji, N.,
Brussee, V., Liu, W., Durand, J.,
Nguyen, M. D., Schmidt, A. M.,
andZochodne,D.W.(2008).Recep-
tor for advanced glycation end
products (RAGEs) and experimen-
tal diabetic neuropathy. Diabetes 57,
1002–1017.
Tracey, K. J. (2009). Reﬂex control of
immunity. Nat. Rev. Immunol. 9,
418–428.
Van Maanen, M. A., Vervoordeldonk,
M. J., and Tak, P. P. (2009). The
cholinergicanti-inﬂammatorypath-
way: towards innovative treatment
of rheumatoid arthritis. Nat. Rev.
Rheumatol. 5, 229–232.
Vinik, A., and Kles, K. (2006). Patho-
physiologyandtreatmentofdiabetic
peripheral neuropathy: the case for
diabetic neurovascular function as
an essential component. Curr. Dia-
betes Rev. 2, 131–145.
Vinik, A., Maser, R., and Ziegler,
D. (2011). Autonomic imbalance:
prophet of doom or scope for hope?
Diabetic Med. 28, 643–651.
Vinik, A., Parson, H., and Ullal, J.
(2006a). The role of PPARs in the
microvascular dysfunction in dia-
betes. Vascul. Pharmacol. 45, 54–64.
Vinik, A., Ullal, J., Parson, H. K.,
and Casellini, C. M. (2006b). Dia-
betic neuropathies: clinical man-
ifestations and current treatment
options.Nat.Clin.Pract.Endocrinol.
Metab. 2, 269–281.
Vinik, A. I., and Erbas, T. (2006). Car-
diovascular autonomic neuropathy:
diagnosis and management. Curr.
Diab. Rep. 6, 424–430.
Vinik,A. I., Maser, R. E., and Ziegler, D.
(2010). Neuropathy: the crystal ball
for cardiovascular disease? Diabetes
Care 33, 1688–1690.
Vinik,A. I., and Ziegler, D. (2007). Dia-
beticcardiovascularautonomicneu-
ropathy. Circulation 115, 387–397.
von Kanel, R., Nelesen, R. A., Mills,
P. J., Ziegler, M. G., and Dimsdale,
J. E. (2008). Relationship between
heart rate variability, interleukin-6,
and soluble tissue factor in healthy
subjects. Brain Behav. Immun. 22,
461–468.
Wakabayashi, S., and Aso, Y. (2004).
Adiponectin concentrations in sera
from patients with type 2 diabetes
are negatively associated with sym-
pathovagal balance as evaluated by
power spectral analysis of heart
rate variation. Diabetes Care 27,
2392–2397.
Watkins, L. R., Goehler, L. E., Relton, J.
K., Tartaglia, N., Silbert, L., Martin,
D., and Maier, S. F. (1995). Block-
ade of interleukin-1 induced hyper-
thermia by subdiaphragmatic vago-
tomy: evidence for vagal mediation
of immune-brain communication.
Neurosci. Lett. 183, 27–31.
Wess, J., Eglen, R. M., and Gautam,
D. (2007). Muscarinic acetylcholine
receptors: mutant mice provide new
insights for drug development. Nat.
Rev. Drug Discov. 6, 721–733.
Witzke, K., Vinik, A., Grant, L., Parson,
H., and Pittenger, G. (2011). Loss of
RAGE defense: a cause of Charcot
neuroarthropathy?DiabetesCare 34,
1617–1621.
Wu, J. S., Yang, Y. C., Lin, T. S., Huang,
Y. H., Chen, J. J., Lu, F. H., Wu, C.
H., and Chang, C. J. (2007). Epi-
demiologicalevidenceofalteredcar-
diac autonomic function in subjects
with impaired glucose tolerance but
not isolated impaired fasting glu-
cose. J. Clin. Endocrinol. Metab. 92,
3885–3889.
Ziegler, D., Hanefeld, M., Ruhnau, K. J.,
Meissner,H.P.,Lobisch,M.,Schutte,
K.,andGries,F.A.(1995).Treatment
of symptomatic diabetic peripheral
neuropathy with the anti-oxidant
alpha-lipoic acid. A 3-week multi-
centre randomized controlled trial
(ALADIN Study). Diabetologia 38,
1425–1433.
Ziegler, D., Low, P. A., and Boulton, A.
J. M. (2011). Antioxidant treatment
with alpha-lipoic acid in diabetic
polyneuropathy: a 4-year random-
ized double-blind trial (NATHAN
1). Diabetologia 50, S63.
Ziegler,D.,Schatz,H.,Conrad,F.,Gries,
F. A., Ulrich, H., and Reichel, G.
(1997). Effects of treatment with
the antioxidant alpha-lipoic acid
on cardiac autonomic neuropathy
in NIDDM patients. A 4-month
randomized controlled multicenter
trial(DEKANStudy).DeutscheKar-
diale Autonome Neuropathie. Dia-
betes Care 20, 369–373.
Ziegler, D., Zentai, C. P., Perz, S., Rath-
mann, W., Haastert, B., Doring, A.,
and Meisinger,C. (2008). Prediction
of mortality using measures of car-
diac autonomic dysfunction in the
diabetic and nondiabetic popula-
tion:theMONICA/KORAAugsburg
Cohort Study. Diabetes Care 31,
556–561.
Conﬂict of Interest Statement: The
author declares that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 19 January 2012; accepted: 07
May 2012; published online: 21 June
2012.
Citation: Vinik AI (2012) The
conductor of the autonomic orches-
tra. Front. Endocrin. 3:71. doi:
10.3389/fendo.2012.00071
This article was submitted to Frontiers
in Diabetes, a specialty of Frontiers in
Endocrinology.
Copyright © 2012 Vinik. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tionNonCommercialLicense,whichper-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org June 2012 | Volume 3 | Article 71 | 13